REG - RUA Life Sciences - Change of Nominated Adviser and Broker

Rua Life SciencesAnnouncement

01/11/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231101:nRSA0991Sa&default-theme=true

RNS Number : 0991S  RUA Life Sciences PLC  01 November 2023

1 November 2023

 

Rua Life Sciences plc

 

("RUA Life Sciences", the "Company" or the "Group")

 

Change of Nominated Adviser and Broker

 

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical
device businesses focused on the exploitation of Elast-Eon™, the world
leading long-term implantable biostable polyurethane, announces that,
following the completion of the all-share merger between Cavendish Securities
plc (previously named Cenkos Securities plc) and Cavendish Financial plc
(previously named finnCap Group plc), and as a consequence of internal
reorganisation within the Cavendish Group, the Company has changed its
Nominated Adviser and Broker from Cavendish Securities plc to Cavendish
Capital Markets Limited.

 

 

For further information contact:

 

RUA Life Sciences

Bill Brown, Chairman
                      Tel: +44 (0)1294 317073

Caroline Stretton, Group Managing Director
 Tel: +44 (0)1294 317073

 

 

Cavendish Capital Markets Limited
       Tel: +44 (0)20 7220 0500

(Nominated Adviser and Broker)

Giles Balleny / Dan Hodkinson (Corporate Finance)

Michael Johnson (Sales)

 

 

About RUA Life Sciences

 

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the Group's four
trading businesses, each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by enabling medical
devices with Elast-Eon(TM), the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-Eon(TM), manufacturing a device or
component, or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 

 RUA Contract Manufacture:  End-to-end contract developer and manufacturer of medical devices and
                            implantable fabric specialist.

 RUA Biomaterials:          Licensor of Elast-Eon(TM) polymers to the medical device industry.

 RUA Vascular:              Commercialisation of open surgical vascular grafts and patches

 RUA Structural Heart:      Development of polymeric leaflet systems for heart valves.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPDFLFBXFLBFBZ